| Budget Amount *help |
¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2017: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2016: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2015: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
|---|
| Outline of Final Research Achievements |
Accumulating evidence suggests that the continuous conversion of normal form of prion protein (PrPC) into abnormal form of PrP (PrPSc) in affected hosts plays a central role of the pathogenesis of prion diseases. However, the molecular basis of the diversity and transmissibility in PrPSc formation has not been well understood. Using the protein misfolding cyclic amplification (PMCA) technique, we found that some cofactors such as heparin sulfate or its analog heparin greatly enhanced the formation of PrPSc in vitro. Furthermore, we developed an advanced PMCA system using E-coli derived recombinant PrP as a substrate. We currently examined the diversity and transmissibility of the advanced PMCA products.
|
